Emerging and re-emerging viral diseases, predisposing risk factors, and implications of international travel: a call for action for increasing vigilance and imposing restrictions under the current threats of recently emerging multiple Omicron subvariants.
作者信息
Kaiwan Oroshay, Sethi Yashendra, Khehra Nimrat, Padda Inderbir, Chopra Hitesh, Chandran Deepak, Dhama Kuldeep, Chakraborty Chiranjib, Islam Md Aminul, Kaka Nirja
机构信息
PearResearch, Dehradun, Uttarakhand, India.
Northeast Ohio Medical University, Ohio, USA.
出版信息
Int J Surg. 2023 Mar 1;109(3):589-591. doi: 10.1097/JS9.0000000000000176.
Abstract
摘要
相似文献
1
Emerging and re-emerging viral diseases, predisposing risk factors, and implications of international travel: a call for action for increasing vigilance and imposing restrictions under the current threats of recently emerging multiple Omicron subvariants.新出现和再次出现的病毒性疾病、诱发风险因素及国际旅行的影响：呼吁采取行动，在近期出现多种奥密克戎亚变体的当前威胁下提高警惕并实施限制措施。
Int J Surg. 2023 Mar 1;109(3):589-591. doi: 10.1097/JS9.0000000000000176.
2
Omicron Subvariants Infection Kinetics and Nirmatrelvir Efficacy in Transgenic K18-hACE2 Mice.奥密克戎亚变体在转基因K18-hACE2小鼠中的感染动力学及奈玛特韦疗效
bioRxiv. 2025 Jul 25:2025.07.25.666822. doi: 10.1101/2025.07.25.666822.
3
Genetic and Immunological Profiling of Recent SARS-CoV-2 Omicron Subvariants: Insights into Immune Evasion and Infectivity in Monoinfections and Coinfections.新冠病毒奥密克戎变种新亚型的基因和免疫特征分析：单重感染和合并感染中免疫逃逸及传染性的见解
Viruses. 2025 Jun 27;17(7):918. doi: 10.3390/v17070918.
4
Immunogenicity, clinical efficacy and safety of additional second COVID-19 booster vaccines against Omicron and its subvariants: A systematic review.奥密克戎及其亚变种的额外第二剂 COVID-19 加强疫苗的免疫原性、临床疗效和安全性：系统评价。
Rev Med Virol. 2024 Jan;34(1):e2515. doi: 10.1002/rmv.2515.
5
Omicron Subvariants: Clinical, Laboratory, and Cell Culture Characterization.奥密克戎亚变体：临床、实验室及细胞培养特征
medRxiv. 2022 Sep 23:2022.09.20.22280154. doi: 10.1101/2022.09.20.22280154.
6
Household clusters of SARS-CoV-2 Omicron subvariants contemporaneously sequenced from dogs and their owners.从狗及其主人身上同时测序的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎亚变体的家庭聚集情况。
mSphere. 2025 Jul 2:e0007425. doi: 10.1128/msphere.00074-25.
7
A panel of multivalent nanobodies broadly neutralizing Omicron subvariants and recombinant.一组多价纳米抗体广泛中和奥密克戎亚变体和重组体。
J Med Virol. 2024 Mar;96(3):e29528. doi: 10.1002/jmv.29528.
8
Impact of imported COVID-19 cases on South Korea's response: variant transitions and regional patterns (2020-2023).输入性新冠病例对韩国应对措施的影响：变异株演变与区域模式（2020 - 2023年）
BMC Infect Dis. 2025 Jul 1;25(1):820. doi: 10.1186/s12879-025-11260-3.
9
Immunogenicity of monovalent and multivalent subunit vaccines against SARS-CoV-2 variants in mice with divergent vaccination history.具有不同疫苗接种史的小鼠中，单价和多价亚单位疫苗针对新冠病毒变异株的免疫原性。
Microbiol Spectr. 2025 Jul 17:e0290724. doi: 10.1128/spectrum.02907-24.
10
New variants of COVID-19 (XBB.1.5 and XBB.1.16, the "Arcturus"): A review of highly questioned concerns, a brief comparison between different peaks in the COVID-19 pandemic, with a focused systematic review on expert recommendations for prevention, vaccination, and treatment measures in the general population and at-risk groups.新型冠状病毒变异株（XBB.1.5 和 XBB.1.16，即“Arcturus”）：备受质疑的问题综述，对 COVID-19 大流行不同高峰期的简要比较，以及对普通人群和高危人群预防、接种和治疗措施的专家建议进行的重点系统评价。
Immun Inflamm Dis. 2024 Jun;12(6):e1323. doi: 10.1002/iid3.1323.
引用本文的文献
1
Dynamic modeling of mortality risk factors in Ebola virus disease using logistic regression on unbalanced panel data from a randomized controlled trial in the Democratic Republic of Congo.利用刚果民主共和国一项随机对照试验的不平衡面板数据进行逻辑回归，对埃博拉病毒病死亡风险因素进行动态建模。
PLOS Glob Public Health. 2025 Jul 11;5(7):e0004901. doi: 10.1371/journal.pgph.0004901. eCollection 2025.
2
Consensus Statements on Assessments and Vaccinations Prior to Commencement of Advanced Therapies for the Treatment of Inflammatory Bowel Diseases.炎症性肠病高级治疗开始前评估和疫苗接种的共识声明。
Aliment Pharmacol Ther. 2025 Jan;61(1):132-144. doi: 10.1111/apt.18318. Epub 2024 Oct 10.
3
Recent Advances on Targeting Proteases for Antiviral Development.靶向蛋白酶用于抗病毒药物研发的最新进展
Viruses. 2024 Feb 27;16(3):366. doi: 10.3390/v16030366.
本文引用的文献
1
Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2.奥密克戎变异株 BQ.1、BQ.1.1、BA.4.6、BF.7 和 BA.2.75.2 增强型中和抗性。
Cell Host Microbe. 2023 Jan 11;31(1):9-17.e3. doi: 10.1016/j.chom.2022.11.012. Epub 2022 Nov 22.
2
Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies.全球新兴的 SARS-CoV-2 奥密克戎变异株：影响、挑战与策略。
J Infect Public Health. 2023 Jan;16(1):4-14. doi: 10.1016/j.jiph.2022.11.024. Epub 2022 Nov 19.
3
Subvariant 'soup' may drive wave.亚变体“混合体”可能推动疫情浪潮。
New Sci. 2022 Nov 5;256(3411):11. doi: 10.1016/S0262-4079(22)01970-4. Epub 2022 Nov 4.
4
Evidence for SARS-CoV-2 Delta and Omicron co-infections and recombination.SARS-CoV-2 Delta 和 Omicron 共感染和重组的证据。
Med. 2022 Dec 9;3(12):848-859.e4. doi: 10.1016/j.medj.2022.10.002. Epub 2022 Oct 20.
5
Travel in the Time of COVID: A Review of International Travel Health in a Global Pandemic.新冠疫情下的旅行：全球大流行期间国际旅行健康综述
Curr Infect Dis Rep. 2022;24(10):129-145. doi: 10.1007/s11908-022-00784-3. Epub 2022 Aug 4.
6
Framework for assessing and easing global COVID-19 travel restrictions.评估和放宽全球 COVID-19 旅行限制的框架。
Sci Rep. 2022 Apr 28;12(1):6985. doi: 10.1038/s41598-022-10678-y.
7
Vaccine passports around the world.世界各地的疫苗护照。
BMJ. 2021 Sep 1;374:n2142. doi: 10.1136/bmj.n2142.
8
COVID-19 Point-of-Care Diagnostics: Present and Future.COVID-19即时检测诊断：现状与未来。
ACS Nano. 2021 May 25;15(5):7899-7906. doi: 10.1021/acsnano.1c02981. Epub 2021 May 13.
9
International travel-related control measures to contain the COVID-19 pandemic: a rapid review.国际旅行相关防控措施以遏制 COVID-19 大流行：快速综述。
Cochrane Database Syst Rev. 2021 Mar 25;3(3):CD013717. doi: 10.1002/14651858.CD013717.pub2.
10
COVID-19 in comparison with other emerging viral diseases: risk of geographic spread via travel.与其他新出现的病毒性疾病相比的新型冠状病毒肺炎：通过旅行实现地理传播的风险
Trop Dis Travel Med Vaccines. 2021 Jan 31;7(1):3. doi: 10.1186/s40794-020-00129-9.
Zotero 插件